OncoBone Ventures

OncoBone Ventures Limited develops novel therapies for cancer patients with bone metastases utilizing a novel innovative osteoimmuno-oncology (OIO©) concept established by its founders.

Osteoimmuno-oncology (OIO) refers to interactions of cancer, bone and immune cells, three compartments important in regulating growth of bone metastases. Efficacy of therapies is confirmed utilizing our preclinical Bone Metastasis Technology Platform©, followed by regulatory safety studies to complete IND-ready packages. The therapeutic assets are then outlicensed to larger pharma or biotech companies for clinical development.

Key Numbers

19 .3 m

New cancer cases globally in 2020, expected to increase to 28.6m by 2040

10 m

Cancer deaths globally in 2020
(one in six of all deaths), mainly caused by metastases

70-90%

Advanced stage breast and prostate cancer patients develop bone metastases

5 %

Patients with bone metastases alive five years after the diagnosis
(no effective treatments available)

30 bn

Cancer immunotherapy market value in 2019, estimated to more than triple to $95bn by 2026

Pipeline

The pipeline of OncoBone Ventures includes two series of therapeutic assets, OBP series that are co-developed with original inventors of the assets, and OB series that are our own assets developed utilizing our patented Biomarker Discovery Engine.

Investors

OncoBone Ventures seeks investor funding for our drug development programs. The company expects to generate profitable business within three years after completing the first funding round, after which the company needs no further external funding and will be a target for profitable exit through IPO or trade sale.

OBP-001
Q3 2024
OBP-002
Q4 2024
OB-series
Q4 2026

Pipeline

The current pipeline of OncoBone Ventures includes four therapeutic assets that are co-developed with original inventors of the assets. In addition, several potential assets are under evaluation.

Investors

OncoBone Ventures seeks investor funding for our drug development programs. The company expects to generate profitable business within three years after completing the first funding round, after which the company needs no further external funding and will be a target for profitable exit through IPO or trade sale.

News & Media